Melaiu, Ombretta <br/><br/>
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Aug 2017 
 - 4462-4472 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-16-2601  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antigens, CD--genetics<br/>Azepines--administration & dosage<br/>B7-H1 Antigen--genetics<br/>Biomarkers, Tumor--genetics<br/>Cell Line, Tumor<br/>Child<br/>Child, Preschool<br/>Female<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Genes, MHC Class I--genetics<br/>Humans<br/>Infant<br/>Lymphocytes, Tumor-Infiltrating--drug effects<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>N-Myc Proto-Oncogene Protein--genetics<br/>Neuroblastoma--drug therapy<br/>Prognosis<br/>Programmed Cell Death 1 Receptor--genetics<br/>Proto-Oncogene Proteins c-myc--genetics<br/>Triazoles--administration & dosage<br/>Lymphocyte Activation Gene 3 Protein